In recent years, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) have been recognized as a central players and regulators of cancer cell proliferation, apoptosis and angiogenesis and, therefore, as a potentially relevant therapeutic target. Several strategies for EGFR and VEGF targeting have been developed, the most successful being represented by monoclonal antibodies (MAbs), that directly interfere with ligand-receptor binding and small molecule tyrosine kinase inhibitors (TKIs), that interfere with activation/phophorylation of EGFR and VEGF. These agents have been authorized in advanced cancers, including , non small cell lung cancer (NSCLC)

Ruolo dei nuovi farmaci nel tumore del polmone

BIANCO, Andrea
2008

Abstract

In recent years, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) have been recognized as a central players and regulators of cancer cell proliferation, apoptosis and angiogenesis and, therefore, as a potentially relevant therapeutic target. Several strategies for EGFR and VEGF targeting have been developed, the most successful being represented by monoclonal antibodies (MAbs), that directly interfere with ligand-receptor binding and small molecule tyrosine kinase inhibitors (TKIs), that interfere with activation/phophorylation of EGFR and VEGF. These agents have been authorized in advanced cancers, including , non small cell lung cancer (NSCLC)
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11591/329193
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact